WW · Ww International, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. WW reaffirmed full-year 2026 guidance and posted Q2 Clinical subscription revenue growth of 30.4% with Clinical subscribers up 55.7% YoY, while total revenue declined 14.2% to $162.3 million as Behavioral subscription revenue fell 22.7% and behavioral end-of-period subscribers dropped 24.6% YoY.
- + Clinical subscription revenue grew 30.4% to $39.9 million and clinical end-of-period subscribers rose 55.7% YoY to 197,000
- + Core+ subscribers reached 541,000, up 13.9% YoY, marking the third consecutive quarter of sequential growth in the higher-value behavioral tier
- + ARPU rose 10.2% YoY and adjusted gross margin held at a near-record 73.6% despite the mix shift toward clinical
- − Total Q2 revenue declined 14.2% YoY to $162.3 million from $189.2 million
- − Behavioral subscription revenue fell 22.7% YoY to $121.5 million and behavioral end-of-period subscribers declined 24.6% YoY to 2.3 million
- − Adjusted EBITDA of $39.8 million was well below the $65.3 million in the prior-year quarter
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA Margin non-GAAP | 24.5% | Q2 2026 | — |
| Adjusted Gross Margin non-GAAP | 73.6% | Q2 2026 | — |
| Core+ End of Period Subscribers | 541K | Q2 2026 | — |
| End of Period Behavioral Subscribers | 2.29M | Six Months Ended June 30, 2026 | — |
| End of Period Clinical Subscribers | 197K | Six Months Ended June 30, 2026 | — |
| End of Period Subscribers | 2.49M | Six Months Ended June 30, 2026 | — |
| Incoming Behavioral Subscribers | 2.63M | Six Months Ended June 30, 2026 | — |
| Incoming Clinical Subscribers | 130K | Six Months Ended June 30, 2026 | — |
| Incoming Subscribers | 2.76M | Six Months Ended June 30, 2026 | — |
| Marketing expense as a percentage of Revenue | 29.5% | Q2 2026 | — |
| Monthly Behavioral Subscription Revenue Per Average Subscriber | $16.91 | Six Months Ended June 30, 2026 | — |
| Monthly Clinical Subscription Revenue Per Average Subscriber | $75.13 | Six Months Ended June 30, 2026 | — |
| Monthly Subscription Revenue Per Average Subscriber | $20.76 | Six Months Ended June 30, 2026 | — |
| Monthly Subscription Revenue Per Average Subscriber (ARPU) growth | 10.2% | Q2 2026 | — |
| Total End of Period Subscribers | 2.5M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
WW
this stock
Ww International, Inc.
|
$143.53M | -49.5% | +12.2% | — | 17.1% |
|
HCA
HCA Healthcare, Inc.
|
$96.64B | -8.6% | +7.1% | 15.0 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.92B | -13.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.91B | +30.1% | +0.9% | 10.0 | 2.5% |
|
FMS
Fresenius Medical Care AG
|
$12.08B | -6.6% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| WW | +2.7% | -16.8% | +34.2% | -4.7% | -49.6% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +2.9% | -16.3% | +22.1% | -5.6% | -62.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.